PMID- 18276020
OWN - NLM
STAT- MEDLINE
DCOM- 20080715
LR  - 20080331
IS  - 0166-3542 (Print)
IS  - 0166-3542 (Linking)
VI  - 78
IP  - 3
DP  - 2008 Jun
TI  - Rectal immunization generates protective immunity in the female genital tract 
      against herpes simplex virus type 2 infection: relative importance of myeloid 
      differentiation factor 88.
PG  - 202-14
LID - 10.1016/j.antiviral.2007.12.014 [doi]
AB  - The present study was undertaken to examine the potential of rectal route of 
      immunization for induction of protective immunity in the female genital tract 
      against genital herpes infection in mice. A single rectal immunization of female 
      C57Bl/6 mice with live attenuated herpes simplex virus type 2 lacking thymidine 
      kinase (HSV-2 TK-) was shown to confer HSV-specific cellular and humoral immune 
      responses as well as protection against an otherwise lethal vaginal challenge 
      with a virulent HSV-2 strain. The immunity afforded by rectal immunization with 
      HSV-2 TK- was shown to be independent of sex hormonal influence and the usage of 
      the adaptor protein myeloid differentiation factor 88 (MyD88). Next, the impact 
      of rectal immunization with HSV-2 glycoprotein D (gD) in combination with CpG 
      oligodeoxynucleotide (ODN) or cholera toxin (CT) on induction of immunity against 
      HSV-2 was investigated. Rectal immunization of mice with gD+CpG failed to 
      generate gD specific immune responses and protection against genital herpes 
      infection. Conversely, rectal immunization with gD+CT elicited potent gD-specific 
      cellular immune responses and protection against genital herpes infection through 
      a MyD88-dependent manner. These results highlight the potential of rectal route 
      for the development of novel immunization strategies to elicit immunity in the 
      female genital tract against genital herpes and presumably other sexually 
      transmitted diseases.
FAU - Tengvall, Sara
AU  - Tengvall S
AD  - Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska 
      Academy at Goteborg University, Medicinaregatan 7A, Box 435, 40530 Goteborg, 
      Sweden.
FAU - O'Hagan, Derek
AU  - O'Hagan D
FAU - Harandi, Ali M
AU  - Harandi AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080124
PL  - Netherlands
TA  - Antiviral Res
JT  - Antiviral research
JID - 8109699
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Herpes Simplex Virus Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myeloid Differentiation Factor 88)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (glycoprotein D-herpes simplex virus type 2)
RN  - 9012-63-9 (Cholera Toxin)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Administration, Intravaginal
MH  - Administration, Rectal
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Cell Line
MH  - Cholera Toxin/immunology
MH  - Female
MH  - Herpes Genitalis/immunology/prevention & control/virology
MH  - Herpes Simplex Virus Vaccines/administration & dosage/genetics/immunology
MH  - Herpesvirus 2, Human/immunology
MH  - Humans
MH  - Immunity, Mucosal
MH  - Immunization
MH  - Immunoglobulin G/blood
MH  - Lymphocyte Activation/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Myeloid Differentiation Factor 88/genetics/*metabolism
MH  - Viral Envelope Proteins/genetics/immunology
EDAT- 2008/02/16 09:00
MHDA- 2008/07/17 09:00
CRDT- 2008/02/16 09:00
PHST- 2007/06/27 00:00 [received]
PHST- 2007/12/17 00:00 [revised]
PHST- 2007/12/21 00:00 [accepted]
PHST- 2008/02/16 09:00 [pubmed]
PHST- 2008/07/17 09:00 [medline]
PHST- 2008/02/16 09:00 [entrez]
AID - S0166-3542(08)00003-X [pii]
AID - 10.1016/j.antiviral.2007.12.014 [doi]
PST - ppublish
SO  - Antiviral Res. 2008 Jun;78(3):202-14. doi: 10.1016/j.antiviral.2007.12.014. Epub 
      2008 Jan 24.